|
|
News Breaks
|
August 2, 2011
|
| 07:56 EDT |  | RIGL |
| theflyonthewall.com: | Rigel Pharmaceuticals on track for US/European NDA filing dates in 2013 | | AZ recently reported that their Phase 3 clinical development program, or OSKIRA, to investigate fostamatinib as a treatment for rheumatoid arthritis is progressing well. AZ expects the first set of data in the second half of 2012 and expects to remain on track to meet the planned US and European new drug application, or NDA, filing dates in 2013. AZ also announced that in the Q1 of 2011 they had commenced a Phase 2b clinical trial, or OSKIRA 4, that explores fostamatinib as a monotherapy in rheumatoid arthritis. This trial will provide important information on the profile of fostamatinib without concomitant treatment with a disease-modifying anti-rheumatic drug. Rigel Investor/Analyst Day Rigel plans to host an investor/analyst day on October 13, 2011 in New York City to present its product development pipeline with a focus on R343, Rigel's inhaled syk inhibitor for asthma. At this event, members of Rigel's management team will present the Phase 1 allergen challenge data for R343 in mild asthmatics as well as the proposed design for the Phase 2 clinical trial for R343 in asthma that is expected to commence in the first half of 2012. :theflyonthewall.com |
|
|
News For RIGL From The Last 14 Days Check below for free stories on RIGL the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 16, 2012
|
| 07:32 EDT | | RIGL |
|
|
|
|
|
Subscribe for More Information